26
Oct
2023

Merck’s ADC Wager, Roche Enters TL1A Rivalry, & OrbiMed Signals Time to Buy

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more.

You may also like

Genentech’s Bet on NC, GSK Buys Boston Liver Drug, & Septerna Entices Novo
NewLimit’s Anti-Aging Bounty, a Twist Spinout, & AI Coming to the FDA
FDA in Crisis, Parker Institute Snags Big Fish, & Merida Megaround
FDA Gutted, Novartis Kidney Drug Pays Off, and Isomorphic Raises a Fortune